Treatment algorithm for immune effector cell–associated hematotoxicity. ∗High risk defined as previous history of hematopoietic stem cell transplantation, baseline cytopenia, high tumor burden, systemic inflammation, and presence of BM infiltration. ∗∗Antifungal prophylaxis particularly recommended in patients with previous invasive fungal disease, previous allo-HCT, and receiving corticosteroids (long-term >72 hour or high dose). Decision for/against antibacterial prophylaxis should incorporate local bacterial epidemiology (eg, prevalence for multidrug-resistant gram-negative bacteria); not recommended for patients with a low-risk profile for ICAHT. ^†Also extends to late ICAHT if these criteria are met.